Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF KIDNEY DISEASES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-11-06
DOI
10.1053/j.ajkd.2021.09.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial
- (2020) Ameur M. Manceur et al. CURRENT MEDICAL RESEARCH AND OPINION
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2019) Rajiv Saran et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA ‐ REG OUTCOME trial
- (2019) A. Kansal et al. DIABETIC MEDICINE
- Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian population in the EMPA-REG OUTCOME Trial
- (2019) Kohei Kaku et al. CLINICAL THERAPEUTICS
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine: A Reference, Not a Rule Book
- (2018) Cristina Carias et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
- (2018) George Gourzoulidis et al. CLINICAL DRUG INVESTIGATION
- The Landscape of Diabetic Kidney Disease in the United States
- (2018) O. Kenrik Duru et al. Current Diabetes Reports
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM
- (2018) O. Reifsnider et al. VALUE IN HEALTH
- New pharmacological strategies for protecting kidney function in type 2 diabetes
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
- (2017) Christoph Wanner et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes 2030: Insights from Yesterday, Today, and Future Trends
- (2017) William R. Rowley et al. Population Health Management
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
- (2016) Maryam Afkarian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- EQ-5D Scores for Diabetes-Related Comorbidities
- (2016) Patrick W. Sullivan et al. VALUE IN HEALTH
- Cost Effectiveness of Empagliflozin in Patients with T2DM and High CV Risk in Canada
- (2016) SR Mettam et al. VALUE IN HEALTH
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Epidemiology of Diabetic Kidney Disease
- (2013) Anne T. Reutens MEDICAL CLINICS OF NORTH AMERICA
- Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study
- (2012) Susan Grandy et al. Health and Quality of Life Outcomes
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started